A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Sponsor: Leap Therapeutics, Inc.
Terminated
Product development discontinued unrelated to safety.
Other terminated trials from Leap Therapeutics, Inc.
More terminations from Leap Therapeutics, Inc.
A PHASE1 clinical study on Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer and Advanced Metastatic Castration-Resistant Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by Leap Therapeutics, Inc. and has accumulated 11 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Jan 2021 — Dec 2023 [monthly]
Terminated PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 6 earlier versions
-
Dec 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Leap Therapeutics, Inc.
- Merck KGaA, Darmstadt, Germany
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .